The Small Saphenous Vein: An Underestimated Source for Autologous Distal Vein Bypass.


Journal

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
ISSN: 1532-2165
Titre abrégé: Eur J Vasc Endovasc Surg
Pays: England
ID NLM: 9512728

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 19 12 2017
accepted: 22 01 2019
pubmed: 3 3 2019
medline: 9 4 2020
entrez: 3 3 2019
Statut: ppublish

Résumé

The small saphenous vein (SSV) is a potential vein source for bypass if neither greater saphenous vein nor arm vein is available. This study reports experience using SSV as part of an all autologous vein bypass policy. This study comprised single centre retrospective data analysis of all consecutive patients treated at an academic tertiary referral centre from January 1998 to February 2017 using the SSV as the main peripheral bypass graft. Study endpoints were primary patency, secondary patency, limb salvage, and survival. One hundred and twenty operations were performed in 118 patients using SSV. Indications were peripheral arterial occlusive disease (n = 91; Rutherford classification 3: n = 11; 4: n = 21; 5,6: n = 59), acute ischaemia (n = 14), popliteal artery aneurysm (n = 12), and bypass revisions (n = 3). Median follow up was 30.5 months (10 months-13.7 years). Primary patency after one, three and five years was 68% (CI: 59-77%), 58% (49-68%), and 54% (45-64%). Secondary patency was 83% (76-89%) after one year and 77% (69-85%) after three and five years. Limb salvage after one year was 88% (82-94%) and 78% (70-86%) after five years. Survival was 96% (92-99%) after one year and 91% (85-97%) at five years. Multivariable analysis identified redo surgery as an independent risk factor. Patients receiving a primary (n = 59) vs. a redo bypass (n = 61) were compared. Primary patency and secondary patency were both significantly better in the primary bypass group than in the redo group (p = .0036 and p = .0003, respectively). Limb salvage was also significantly better in primary bypass patients than in the redo group (p = .0007), whereas overall survival did not differ significantly (p = .48). The SSV is a valuable alternative vein graft in peripheral bypass surgery. It achieves excellent long-term results, particularly in patients with primary procedures but also acceptable results in patients with redo surgery.

Identifiants

pubmed: 30824403
pii: S1078-5884(19)30054-1
doi: 10.1016/j.ejvs.2019.01.023
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

556-563

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.

Auteurs

Patrick Nierlich (P)

Department of Vascular and Endovascular Surgery, University Hospital Salzburg, Austria. Electronic address: p.nierlich@salk.at.

Peter Metzger (P)

Department of Vascular and Endovascular Surgery, University Hospital Salzburg, Austria.

Florian K Enzmann (FK)

Department of Vascular and Endovascular Surgery, University Hospital Salzburg, Austria.

Manuela Aspalter (M)

Department of Vascular and Endovascular Surgery, University Hospital Salzburg, Austria.

Werner Dabernig (W)

Department of Vascular and Endovascular Surgery, University Hospital Salzburg, Austria.

Wolfgang Hitzl (W)

Research Office (Biostatistics), Paracelsus Medical University Salzburg, Austria.

Klaus Linni (K)

Department of Vascular and Endovascular Surgery, University Hospital Salzburg, Austria.

Thomas Hölzenbein (T)

Department of Vascular and Endovascular Surgery, University Hospital Salzburg, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH